NCYT
NEUTRALNovacyt Announces AGM Voting Details
The healthcare company provides details on the upcoming Annual General Meeting, including instructions for shareholders to vote in advance.
Novacyt S.A.
47.60GBX
0.63%
Market Cap
33.62M
Volume
17.36k
14% of avg
P/E Ratio
EPS (TTM)
Beta
0.12
Day Range
46.10p - 47.60p
52 Week Range
36.00p47.60p137.00p
47.60p
Upcoming Events
NCYT
NEUTRALNovacyt Announces Notice of Annual General Meeting
The healthcare company has announced the date and details for its upcoming Annual General Meeting.
NCYT
BADNovacyt Reports Widening Losses Despite Revenue Growth in FY2024 Results
The molecular diagnostics firm reported widening losses despite revenue growth, as it grapples with restructuring costs and a challenging market environment. Management aims to reach profitability through cost-cutting and new product launches.
NCYT
NEUTRALNovacyt Announces Upcoming FY 2024 Results Webinar
The healthcare company will report its audited financial results for the year ended 31 December 2024 and host an investor webinar on 30 April 2025.
NCYT
NEUTRALNovacyt Subsidiary Pleads Guilty in Health and Safety Prosecution
The healthcare company's subsidiary has pleaded guilty to health and safety charges, with sentencing scheduled for later this year.
NCYT
NEUTRALNovacyt receives IVDR accreditation for Yourgene QST*R Base assay
The healthcare company has received regulatory accreditation for its pregnancy screening diagnostic test, further strengthening its product portfolio.
NCYT
GOODMolecular diagnostics firm reports 85% revenue surge and operational efficiencies
This molecular diagnostics firm reported an 85% revenue surge, driven by acquisition. Key segments showed organic growth, with new product launches and operational efficiencies promising future gains.
NCYT
NEUTRALNovacyt announces further cost reduction programme
The healthcare company announces plans to consolidate its global facilities, which are expected to improve EBITDA by £2m annually but incur £1.5m in restructuring costs.
NCYT
GOODNovacyt Expands Veterinary Diagnostics Portfolio with New Multiplex Assays
Diagnostic company Novacyt launches new multiplex assays for detecting gastrointestinal diseases in pets, streamlining testing for veterinary labs.
NCYT
NEUTRALNovacyt Appoints Industry Veteran Dr. Ian Gilham as Non-Executive Director
The healthcare company has appointed an industry veteran with a mixed track record as a Non-Executive Director, which could have a minor impact on investor sentiment.